Company Profile · Healthcare

Schrodinger Inc

SDGR · US
Industry
Computational Drug Discovery
Exchange
US
Country
USA
IPO date
Feb 6, 2020
Employees
850
Website
www.schrodinger.com
Current Price
$15.76
Live · Jun 18, 2026
Fair Buy
≤ $14
Margin-of-safety entry
Baillie Growth Score
43/100
Weak
Intrinsic Value · Three-Tier Range Current price $15.76 Live · Within the fair intrinsic-value range

Composite valuation range · conservative $9–$13 / fair $15–$22 / optimistic $28–$42. At $15.76, Within the fair intrinsic-value range.

At publication $15.85 (Jun 5, 2026)

Research on this stock
Schrödinger, Inc.
SDGR · US
Hold
Schrödinger (SDGR) Zen Horizon Research Report

Schrödinger is a physics-based computational drug discovery platform built around FEP+, a gold-standard method, with 19 of the world's top 20 pharma companies as software customers and additional upside from internal and partnered pipelines plus repeat equity monetizations. Its current market value is about $1.1 billion, with roughly $300 million of net cash, while the stock is down 86% from its 2021 peak. Research rating Hold: a real platform with a hard moat and cheap parts, but slower software growth and limited near-term catalysts keep the risk-reward balanced.

Computational Drug Discovery Baillie 43 Jun 5, 2026
About the company

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Financial snapshot
Market cap$1.16B
Revenue (TTM)$254.9M
EBITDA-$158.89M
Profit margin-40.6%
ROE-30.12%
Forward P/E0
EPS-$1.40
52-week range$10.95 – $23.75
Analyst target$20.88
Analyst rating4.5 / 5

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

Background

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.